台灣臨床試驗主持人資料庫|TPIDB

2017-01-17 - 2020-09-30

Phase III

A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Condition/Disease

Gastric Cancer,Gastroesophageal Junction Cancer
Test Drug

Nivolumab/Ipilimumab/Oxaliplatin/Fluorouracil/Leucovorin/Capecitabine

Participate Sites
2Sites

Terminated2Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

洪逸平

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-06-26 - 2024-05-31

Phase III

ONO-4538 Phase 3 study A Multicenter, Randomized, Double-Blind Trial in Subjects with Non-Squamous Non-Small Cell Lung Cancer

Condition/Disease

NSCLC
Test Drug

Nivolumab (ONO-4538)

Participate Sites
12Sites

Terminated10Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

夏德椿

China Medical University Hospital-Taipei

未分科

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

Condition/Disease

Advanced or Recurrent Gastric Cancer
Test Drug

Nivolumab

Participate Sites
12Sites

Terminated10Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2016-08-01 - 2024-12-31

Phase III

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Condition/Disease

Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Test Drug

Xtandi® Soft Capsules 40 mg

Participate Sites
6Sites

Terminated5Sites

馮思中

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃書彬

Kaohsiung Municipal Gangshan Hospital

未分科

2016-12-01 - 2021-12-31

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Condition/Disease

Rheumatoid arthritis
Test Drug

Filgotinib

Participate Sites
12Sites

Terminated11Sites

方耀凡

Linkou Chang Gung Medical Foundation

藍忠亮

China Medical University Hospital-Taipei

未分科

2017-11-01 - 2022-12-31

Phase I/II

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or are Refractory to Standard Therapy.

Condition/Disease

Locally Advanced or Metastatic Urothelial Cell Carcinoma
Test Drug

Vofatamab (B-701)

Participate Sites
9Sites

Terminated8Sites

蘇柏榮

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-12-01 - 2022-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU -LINK)

Condition/Disease

Pneumococcal Infections
Test Drug

15-Valent Pneumococcal Conjugate Vaccine (V114)

Participate Sites
4Sites

Terminated4Sites

邱政洵

Linkou Chang Gung Medical Foundation

Division of Pediatrics

2015-09-01 - 2019-12-31

Phase III

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition/Disease

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

Condition/Disease

TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer
Test Drug

Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2015-10-01 - 2019-12-31

Phase III

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE 119)

Condition/Disease

Metastatic Triple Negative Breast Cancer (mTNBC)
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated4Sites

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

邱昌芳

China Medical University Hospital-Taipei

未分科

Search Result

List